Prime Medicine (PRME) PT Lowered to $7 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts PRME Hot Sheet
Price: $5.24 --0%
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 22 | New: 0
Rating Summary:
11 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 22 | New: 0
Join SI Premium – FREE
Stifel analyst Dae Gon Ha lowered the price target on Prime Medicine (NASDAQ: PRME) to $7.00 (from $8.00) while maintaining a Hold rating.
You May Also Be Interested In
- Morgan Stanley Upgrades Aixtron SE (AIXA:GR) (AIXXF) to Overweight
- Merck (MRK) PT Raised to $165 at BofA Securities
- Cheniere Energy (LNG) PT Raised to $350 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
